The polypill in cardiovascular prevention: Evidence, limitations and perspective-position paper of the European Society of Hypertension

Journal of Hypertension

Volumn 35, Issue 8, 2017, Pages 1546-1553

  Coca, Antonio ^a   Agabiti Rosei, Enrico ^b,c   Cifkova, Renata ^d   Manolis, Athanasios J ^e   Redón, Josep ^f   Mancia, Giuseppe ^g,h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SPEDALI CIVILI   (Italy)

^d CHARLES UNIVERSITY   (Czech Republic)

^e IASO GENERAL HOSPITAL   (Greece)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Istituto Auxologico Italiano   (France)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive treatment; cardiovascular risk; polypill

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PILL; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG FORMULATION; EUROPE; MEDICAL SOCIETY;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG COMPOUNDING; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; SOCIETIES, MEDICAL;

EID: 85021824661     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001390     Document Type: Review

References (93)

1. World Health Organization. Secondary prevention of noncommunicable disease in low and middle income countries through communitybased and health service interventions. WHO-Wellcome Trust Meeting report 1-3. Geneva: World Health Organization; 2002.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360:2-3.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419.
4. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165:1147-1152.
5. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
6. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: A population-based study in Italy. J Hypertens 2008; 26:819-824.
7. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34:2940-2948.
8. Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32:300-310.
9. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107.
10. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 2004; 42:200-209.
11. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, et al., Council on Cardiovascular Nursing; Council on Arteriosclerosis, Thrombosis, Vascular Biology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Nutrition, Physical Activity, Metabolism; Council on Stroke; Preventive Cardiovascular Nurses Association. Managing abnormal blood lipids: A collaborative approach. Circulation 2005; 112:3184-3209.
12. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462-467.
13. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
14. Wang TD, Chen YH, Huang CH, Chen WJ, Chen MF. Bidirectional adherence changes and associated factors in patients switched from free combinations to equivalent single-pill combinations of antihypertensive drugs. Hypertension 2014; 63:958-967.
15. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007; 120:713-719.
16. Kjellgren KI, Ahlner J, Saljo R. Taking antihypertensive medication-controlling or co-operating with patients Int J Cardiol 1995; 47:257-268.
17. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64:1279-1283.
18. Banegas JR, Lopez-Garca E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: The EURIKA study. Eur Heart J 2011; 32:2143-2152.
19. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357:995-1001.
20. Beebe TJ, Davern ME, McAlpine DD, Ziegenfuss JK. Comparison of two within-household selection methods in a telephone survey of substance abuse and dependence. Ann Epidemiol 2007; 17:458-463.
21. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27:963-975.
22. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107:2185-2189.
23. Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: Data from the BP-CARE study. J Hypertens 2013; 31:2018-2024.
24. Kannel WB. Risk stratification in hypertension: New insights from the Framingham study. Am J Hypertens 2000; 13:3S-10S.
25. Muntner P, He J, Roccella EJ, Whelton PK. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002; 39:897-902.
26. Thomas F, Rudnichi A, Bacri AM, Bean K, Guize L, Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37:1256-1261.
27. Messerli FH, Bangalore S. Good news from Lake Wobegon. Am J Med 2006; 119:4-5.
28. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: Results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1498.
29. Mancia G. The association between diabetes and hypertension: An overview of its clinical impact. Dialogues Cardiovasc Med 2016; 21:91-109.
30. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, Sega R. Relationship of office, home, ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45:1072-1077.
31. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al., Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
32. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, EUROASPIRE Study Group. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16:121-137.
33. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al., REACH Registry Investigators. International prevalence, recognition, treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180-189.
34. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
35. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk How far can cardiovascular risk be reduced J Hypertens 2009; 27:1509-1520.
36. Mancia G, Rea F, Cuspidi C, Grassi G, Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens 2017; 35:225-233.
37. Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep 2001; 3:473-480.
38. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12:239-245.
39. Toyoshima H, Takahashi K, Akera T. The impact of side effects on hypertension management: A Japanese survey. Clin Ther 1997; 19:1458-1469.
40. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009; 119:3028-3035.
41. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switchingprescriptions for hypertension.JHumHypertens 1998; 12:533-537.
42. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: A retrospective cohort study in primary care. J Hypertens 2005; 23:2093-2100.
43. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32:214-226.
44. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:315.
45. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
46. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
47. Corrao G, Rea F, Ghirardi A, Soranna D, Merlino L, Mancia G. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66:742-749.
48. Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Pasini TS, et al. Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis 2013; 230:171-176.
49. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al., Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365:2088-2097.
50. Corrao G, et al. Protective effects of antihypertensive treatment in patients aged 85 years or older. J Hypertens. [in press].
51. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-530.
52. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24:121-127.
53. Hirakawa Y, Arima H, Webster R, Zoungas S, Li Q, Harrap S, et al. Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes.JHypertens 2016; 34:781-787.
54. Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, et al. Statins and the risk of diabetes: Evidence from a large populationbased cohort study. Diabetes Care 2014; 37:2225-2232.
55. Hameed MA, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354:i3268.
56. Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L. Use of electronic pill boxes to assess risk of poor treatment compliance: Results of a largescale trial. Am J Hypertens 1999; 12:374-380.
57. Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic disparities in adherence to antihypertensive medications of Medicare part D beneficiaries. J Am Geriatr Soc 2012; 60:1298-1303.
58. Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One 2013; 8:e64914.
59. Gentil L, Vasiliadis HM, Preville M, Berbiche D. Impact of mental disorders on the association between adherence to antihypertensive agents and all-cause healthcare costs. J Clin Hypertens (Greenwich) 2017; 19:75-81.
60. Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, et al. Trends in antihypertensive medication discontinuation and low adherence among Medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 2016; 68:565-575.
61. Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: An analysis from real life data. J Hypertens 2014; 32:1708-1715.
62. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: Results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18:1691-1699.
63. Dusing R. Adverse events, compliance, changes in therapy. Curr Hypertens Rep 2001; 3:488-492.
64. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 326:1427.
65. Nicotra F, Wettermark B, Sturkenboom MC, Parodi A, Bellocco R, Ekbom A, et al. Management of antihypertensive drugs in three European countries. J Hypertens 2009; 27:1917-1922.
66. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58:566-572.
67. Gupta AK, Arshad S, Poulter NR. Compliance, safety, effectiveness of fixed-dose combinations of antihypertensive agents: A metaanalysis. Hypertension 2010; 55:399-407.
68. Corrao G, Soranna D, Arfe A, Casula M, Tragni E, Merlino L, et al. Are generic and brand-name statins clinically equivalent Evidence from a real data-base. Eur J Intern Med 2014; 25:745-750.
69. Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: Evidence from a large population-based study. Eur J Clin Invest 2014; 44:933-939.
70. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, stroke: Systematic review and meta-analysis. BMJ 2003; 326:1423.
71. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: A critical reappraisal. Circ Res 2015; 116:1058-1073.
72. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment Curr Hypertens Rep 2002; 4:278-285.
73. Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5:463-471.
74. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA 2013; 310:918-929.
75. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care. BMJ 2014; 348:g3318.
76. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22:920-930.
77. Fuster V, Sanz G. A polypill for secondary prevention: Time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med 2007; 4:173.
78. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: Rationale, selection of drugs and target population. Nat Clin Prac Cardiovasc Med 2009; 6:101-110.
79. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: Results from the FOCUS project. J Am Coll Cardiol 2014; 64:2071-2082.
80. Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: A polypill for secondary cardiovascular prevention. Int J Cardiol 2015; 201 (Suppl 1):S15-S22.
81. Kolte D, Aronow WS, Banach M. Polypills for the prevention of cardiovascular diseases. Expert Opin Investig Drugs 2016; 22:1-10.
82. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009; 6:112-119.
83. Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, et al. Do polypills lead to neglect of lifestyle risk factors Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol 2016; 23:1393-1400.
84. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
85. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
86. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). Available at: Http://clinical trials.gov/ct2/show/NCT01271985.
87. Castellano JM, Bueno H, Fuster V. The cardiovascular polypill: Clinical data and ongoing studies. Internat J Cardiol 2015; 201 (S1):S8-S14.
88. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J Hypertens 2014; 32:23052314.
89. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 2017; 389:1055-1065.
90. Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet 2017; 389:1066-1074.
91. Corrao G, Mazzola P, Monzio Compagnoni M, Rea F, Merlino L, Annoni G, Mancia G. Antihypertensive medications, loop diuretics, risk of hip fracture in the elderly: A population-based cohort study of 81 617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32:927-936.
92. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371:117-125.
93. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: A systematic review and metaanalysis. JAMA 2015; 313:603-615.